Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLK1 | P53350 | 1/20 | 0.54 |
| ▸ | PPARD | Q03181 | 1/20 | 0.44 |
| ▸ | PPARA | Q07869 | 1/20 | 0.44 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.44 |
| ▸ | TTR | P02766 | 3/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.42 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.42 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.42 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.42 |
| ▸ | TNFRSF1A | P19438 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1796532 | 0.80 | PLK1 (0.46) | PLK1PTGS1TNFRSF1A | |
| SCHEMBL1801192 | 0.76 | PLK1 (0.54) | PLK1PTGS1PTGS2 | |
| SCHEMBL1799551 | 0.74 | PLK1 (0.72) | PLK1CYP2C9 | |
| SCHEMBL404394 | 0.73 | PLK1 (0.71) | PLK1CYP2C9 | |
| Hydrochloric Acid SCHEMBL8186534 | 0.72 | PLK1 (0.69) | PLK1CYP2C9 | |
| SCHEMBL218131 | 0.72 | MAOA (0.52) | CYP1A2CYP3A4CYP2D6CYP2C9CYP2B6 | |
| SCHEMBL218132 | 0.72 | MAOA (0.52) | CYP1A2CYP3A4CYP2D6CYP2C9CYP2B6 | |
| SCHEMBL1963231 | 0.71 | PLK1 (0.68) | PLK1CYP1A2CYP3A4CYP2C9 | |
| SCHEMBL3054006 | 0.71 | PLK1 (0.68) | PLK1CYP2C9 | |
| SCHEMBL403196 | 0.71 | PLK1 (0.71) | PLK1PTGS1PTGS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7951794-B2 | Thiophene derivatives | ACTELION PHARMACEUTICALS LTD. (CH) | 2011-05-31 | — | — | US | disclosed |
| US-20100075946-A1 | NOVEL THIOPHENE DERIVATIVES | ACTELION PHARMACEUTICALS LTD. (CH) | 2010-03-25 | — | — | US | disclosed |
| EP-1896446-A1 | NOVEL THIOPHENE DERIVATIVES | Actelion Pharmaceuticals Ltd. (CH) | 2008-03-12 | — | — | EP | disclosed |
| WO-2006137019-A1 | NOVEL THIOPHENE DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2006-12-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100075946-A1 | NOVEL THIOPHENE DERIVATIVES | TPMT, TSLP, NFATC1 | PLK1 809/4885PPARD 387/4885PPARA 891/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.